CMMB
Chemomab Therapeutics Ltd DRC
NASDAQ: CMMB · HEALTHCARE · BIOTECHNOLOGY
$1.77
-1.67% today
Updated 2026-06-05
Market cap
$12.96M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.12
Dividend yield
—
52W range
$1 – $5
Volume
0.0M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.3
Quality
C+3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-7.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$15.00
+747.46%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -7.55 — distress zone
- Thin margins at 0.00%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27.65M | $-24.22M | $-13.95M | $-8.99M | $-1.77M |
| EPS | — | — | — | — | $-1.12 |
| Free cash flow | $-20.36M | $-23.55M | $-15.46M | $-11.22M | — |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Chemomab Therapeutics Ltd DRC trades at $1.77. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -7.55, it sits in the distress.
Frequently asked questions
What is Chemomab Therapeutics Ltd DRC's stock price?
Chemomab Therapeutics Ltd DRC (CMMB) trades at $1.77.
Is Chemomab Therapeutics Ltd DRC overvalued?
Chemomab Therapeutics Ltd DRC carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Chemomab Therapeutics Ltd DRC (CMMB)?
The 12-month analyst consensus target is $15.00, about 747.5% above the current $1.77. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Chemomab Therapeutics Ltd DRC's Altman Z-Score is -7.55, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-69.68%
Beta0.61
50D MA$1.69
200D MA$2.22
Shares out0.01B
Float0.51B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—